A team of scientists has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease. In mouse models, one tested compound specifically reduced levels of A-beta 42, which is believed to be responsible for the destruction of neurons, but left other essential enzymatic activities in the brain unaffected.